


This issue's topics



Opening the door to novel therapeutic targets for rhabdomyosarcomas

Moretti and colleagues show in this issue that differing levels of two cyclin-dependent kinase inhibitors (cdkIs), p21 and p27, could determine outcome in paediatric rhabdomyosarcomas (RMS). They examined two types of RMS, embryonal (ERMS) and alveolar (ARMS) rhabdomyosarcomas, by the reverse transcriptase-polymerase chain reaction (RT-PCR) and immunohistochemical assays and showed that ERMS, that have a better prognosis, had much higher levels of p21 and p27. They also treated two RMS cell lines, RD and RH-30, with butyrate, a non-toxic antiproliferative drug, that increased the levels of these cdkIs and resulted in the inhibition of cell growth. The authors suggest that “the two genes are potential novel therapeutic targets for rhabdomyosarcomas”.

Detection of circulating neoplastic cells in the blood of lung neuroendocrine carcinoma patients

Begueret and colleagues describe in this issue a novel semi-quantitative reverse transcriptase–polymerase chain reaction and Southern Blotting analysis that has both diagnostic and prognostic value. They analysed *chromogranin* mRNA transcripts in total blood samples from 36 patients (23 with small-cell lung carcinoma (SCLC), 5 with neuroendocrine lung large cell carcinoma (LCC) and 8 with typical carcinoid tumours (TC)). The test was specific and could detect 10 cancer cells/ml of blood. There were no detectable transcripts in the controls or the TC samples. In contrast, 52% of the SCLC and 80% of the LCC cases were positive. Positivity was associated with an approximately 3-fold poorer prognosis and the authors propose that this assay should be compared (in a larger cohort of patients) for its clinical usefulness with a recent immunoradiometric method that could detect chromogranin in serum.

No improvement in DFS and OS following adjuvant endocrine treatment in early endometrial cancer

As endometrial cancer is a hormone-dependent disease then adjuvant hormonal treatment may be useful. Von Minckwitz and colleagues report on data from a trial in 1983–89 where they randomised 388 patients with stage I/II endometrial cancer to receive tamoxifen ($n = 121$) (30 mg/day), medroxy-progesterone acetate (MPA) ($n = 133$) (500 mg/day orally) or to observation ($n = 134$). All patients had undergone surgery consisting of abdominal hysterectomy, bilateral salpingo-oophorectomy and partial colectomy. Adjuvant treatment was continued for 2 years or until disease progression. DFS and OS were the main endpoints. There was no difference in DFS and OS between the groups, although the side-effects were more severe following MPA treatment. There were some differences in the subgroups in these parameters, i.e. in those with stage II disease OS was prolonged for patients treated with tamoxifen. However, these analyses included small numbers of patients. The authors concluded that the trial “failed to reveal a survival benefit for adjuvant MPA and tamoxifen in patients with early stage endometrial carcinoma”.

Forthcoming papers

Editorial Comment

MDR1 inhibition: less resistance, or less relevance?

B. Chabnor

Reviews

Prescribing anticancer drugs in elderly cancer patients

S. Monfardini

The role of new agents in the treatment of non-small cell lung cancer— A review

L.E. Broker, G. Giaccone

Original Papers

Clinical

Neoadjuvant chemotherapy for Ewing's tumour of bone: recent experience at the Rizzoli Orthopaedic Institute

G. Bacci, M. Mercuri, A. Longhi, *et al.*

Immunohistochemical expression of extracellular matrix components tenascin, fibronectin, collagen type IV and laminin in breast cancer: the prognostic value and their role in tumour expansion and progression

E. Ioachim, A. Charchanti, E. Briasoulis, *et al.*

The surgical management of patients following neoadjuvant chemotherapy for locally advanced breast cancer

P. Sauven

Role of thymidine phosphorylase and dihydropyrimidine dehydrogenase in tumour progression and sensitivity to doxifluridine in gastric cancer patients

M. Terashima, H. Fujiwara, A. Takagane, *et al.*

Focal liver lesions in non-Hodgkins lymphoma; an investigation of their prevalence, clinical significance and the role of Hepatitis C virus infection

G. Civardi, D. Vallisa, R. Berte, *et al.*

Phase I and pharmacological studies of the cryptophycin analogue LY355703 administered in a single intermittent or weekly schedule

S. Cristiana, W.-K. Karin, P. Olivia, *et al.*

Results of randomised studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first and second line chemotherapy in advanced soft tissue sarcoma patients

A.T. van Oosterom, H.T. Mouridsen, O.S. Nielsen, P. Dombernowsky, K. Krzemieniecki, I. Judson, L. Svancarova, D. Spooner, C. Hermans, M. Van Glabbeke, J. Verweij for the EORTC STBSG

Phase I and pharmacokinetic studies of PNU-159548, a novel alkylcyclophosphamide, administered intravenously to patients with advanced solid tumours
M.J.A. de Jonge, J. Verweij, A. van der Gaast *et al.*

Paediatric

EVE/CYCLOSPORIN (Etoposide, Vincristine, Epirubicin with high dose Cyclosporin) chemotherapy selected for multidrug resistance modulation

A. Davidson, G. Dick, K. Pritchard-Jones, R. Pinkerton

Epidemiology and Cancer Prevention

Cancer risks in Nordic immigrants and their offspring in Sweden

K. Hemminki, X. Li

Moderate progress for ovarian cancer in the last 20 years: prolongation of survival, but no improvement in the cure rate

J. Engel, R. Eckel, G. Schubert-Fritschle, J. Kerr, W. Kuhn, J. Diebold, R. Kimmig, Rehlock, D. Holzel

Experimental

Deguelin inhibits growth of colon cancer cells through the induction of apoptosis and cell cycle arrest

G. Murillo, G.I. Salti, J.W. Kosmeder II, *et al.*

BCL-2 has differing effects on the sensitivity of breast cancer cells depending on the antineoplastic drug— comparison of multidrug resistance-related and non-related drugs

D. Del Bufalo, A. Biroccio, T. Bruno, *et al.*

Maintenance of PtdIns45P2 pools under limiting inositol conditions, as assessed by liquid chromatography–tandem mass spectrometry and PtdIns45P2 mass evaluation in Ras-transformed cells

C.P. Berrie, L.K. Dragani, J. van der Kaay, *et al.*

Letter

Comments on article by C. Sternberg. *Eur J Cancer* 2002, **38**, 460–467.

P.J. Hoskin